Table 1 Characteristics of randomized trials on CDSS effect on BP or LDL cholesterol
Author, year of publication | Superiority/ Non-inferiority | Inclusion period | Follow up | Guideline adhered | Country | Type of practice | Prevention: primary, secondary or both | Number of participants | Age (mean (sd) or median (range) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
CDSS | Usual Care | CDSS | Usual Care | ||||||||
Patients with an indication for CVRM | |||||||||||
 Anchala et.al, 2015 [65] | Superiority | Aug 2011- March 2012 | 12 months | NR | India | PCP | Primary | 840 | 783 | NR *** | NR |
 Hicks et al, 2008 [66] | Superiority | July 2003 – Feb 2005 | 12 months | JNC VI + VII | USA | PCP | Both (*) | 786 | 1048 | 64 | 61 |
 Montgomery et.al, 2000 [67] | Superiority | Sept 1996 – Sept 1998 | 12 months | NR | UK | PCP | Both (1–17% secondary) | 229 | 157 | 71 (6) | 71 (5) |
 Roumie et. al, 2006 [68] | Superiority | July 2003 – Dec 2003 | 6 months | JNC-VII | USA | Hospital/PCP | Both (*) | 547 | 324 | 65.5 (12.0) | 65.1 (11.9) |
 Eaton et.al, 2011 [69] | Superiority | Oct 2004 - May 3005 | 12 months | ATP III | USA | PCP | Both (*) | 2000 | 2105 | 46.7 ()6.3) | 46.4 (8.4) |
 Gill et.al, 2009 [70] | NR | Nov 2005 – Oct 2006 | 12 months | ATP III | USA | PCP | Both (**) | 26,696 | 37,454 | NR *** | NR |
 Lester et al, 2006 [71] | Superiority | July 2003 – July 2004 | 12 months | NR | USA | PCP | Secondary | 118 | 117 | 64.3 (14.5) | 62.4 (13.3) |
Patients with type II diabetes | |||||||||||
 Ali et.al, 2016 [72] | Superiority | Jan 2011 – June 2012 | 24–36 months | ADA | India and Pakistan | Outpatient clinics | Both (6.8–39.4% secondary | 575 | 571 | 54.2 (9.2) | 54.2 (9.2) |
 Cleveringa et.al, 2008 [73] | Non- inferiority | March 2005 – Aug 2007 | 12 months | Dutch CVRM | NL | PCP | Both (47.1 and 63.3% secondary) | 1699 | 1692 | 65.2 (11.3) | 65.0 (11.0) |
 Glasgow et.al, 2005 [74] | Superiority | 2001–2002 | 12 months | NR | USA | PCP | Both (*) | 379 | 354 | 62 (1.4) | 64 (1.3) |
 Grant et.al, 2008 [75] | Superiority | July 2005 – Sept 2007 | 12 months | NR | USA | PCP | NR | 126 | 118 | 58.8 (10.1) | 53.3 (12.3) |
 Holbrook et.al, 2009 [76] | Superiority | 2002–2003 | 5.9 months (mean) | American/ Canadian Diabetes Association | Canada | PCP | Both (5.5–19% secondary) | 253 | 258 | 61.0 (13.1) | 60.5 (11.9) |
 Ilag et.al, 2003 [77] | Superiority | Oct 1999 – Sept 2000 | 2 years | NR | USA | University affiliated PCP | NR | 83 | 71 | 59 (14) | 59 (120 |
 Maclean et.al, 2009 [78] | Superiority | June 2003 – Jan 2005 | 2 years | NR | Canada | PCP with hospital based clinical laboratories | NR | 3886 | 3526 | 62.4 (19–99) | 63.5 (18–97) |
 Mathers et.al, 2012 [79] | Superiority | 2008–2011 | 12 moths | NICE | UK | PCP | Both (3.2–31.1% secondary) | 95 | 80 | 66 (39–82) | 62 (42–87 |
 Meigs et.al, 2003 [80] | Superiority | May 1998 – April 1999 | 12 months | NR | USA | Hospital based internal medicine clinic | Both (52.4–50.9% secondary) | 307 | 291 | 68 (12) | 67 (12) |
 O’Connor et.al, 2011 [81] | NR | Oct 2006 – May 2007 | 6 months | NR | USA | PCP | Both (11.5–23.4% secondary) | 1194 | 1362 | 57.0 (10.7) | 57.5 (10.1) |